ArticleCell & bioscience2026
Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From diet to hypothalamic dysfunction: Neuroanatomical and hormonal integration of the microbiota-hypothalamus-adipose tissue axis.Reviews in endocrine & metabolic disorders · 2026Review
- Review
- The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aims/hypothesisMetabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally and is closely associated with type 2 diabetes (T2D) and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer partial therapeutic benefits in MASLD, but their efficacy is often limited in advanced insulin-resistant states, highlighting the need for adjunctive strategies to improve treatment responsiveness.
methodsWe investigated the metabolic and mechanistic effects of combining semaglutide (GLP-1RA) with Akkermansia muciniphila 11 (Akk11) in db/db mice, a model of T2D-associated MASLD. Mice were treated with semaglutide alone or in combination with Akk11. Metabolic parameters, hepatic and adipose tissue morphology, gut microbiota composition, transcriptomic profiles, and inflammatory signaling were evaluated.
resultsGLP-1RA monotherapy elicited only modest improvements in glycemia and hepatic lipid accumulation, with effects waning over time. However, Akk11 supplementation significantly enhanced semaglutide therapeutic effects, leading to reduced subcutaneous and visceral fat, improved liver histology, and decreased serum triglycerides. Mechanistically, combination treatment suppressed fatty acid synthesis, promoted mitochondrial function, and remodeled the gut microbiota. Notably, both GLP-1RA and AKK attenuated intestinal pyroptosis pathways, and the combination further suppressed pro-inflammatory markers in the liver and intestine. CONCLUSIONS/
interpretationOur findings highlight a synergistic interaction between GLP-1RA and Akk11, likely mediated through microbiota remodeling and parallel improvements in lipid metabolism across intestinal, hepatic, and adipose compartments. This study supports the development of microbiota-guided strategies to enhance therapies for MASLD and other metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.